AeroVironment's (NASDAQ: AVAV) stock price is poised for a full recovery, driven by surging demand and a record-breaking backlog.
Highlights from the company's Q1 include $1.5 billion in funded backlog, up 37% year over year, and $2.8 billion in total backlog, providing clear visibility into the .... |
Good MorningU.S. stocks came under pressure Thursday as accelerating wholesale inflation, surging crude prices, and rising Treasury yields weighed on risk appetite. Oil climbed above $100 a barrel amid supply constraints and Middle East tensions, lifting energy shares and pushing the United States Oil Fund to a 52-week high. Higher fuel costs also pressured travel names, with Carnival shares falling.
Technology and semiconductor stocks faced broader weakness as investors remained focused on AI spending and valuations. NVIDIA remained in focus after CEO Jensen Huang said cybersecurity will likely be AI’s next major use case, while NVIDIA-backed MediaTek reported August revenue growth of 44% year over year amid AI-chip momentum. Apple shares rose after the company introduced its $1,999 foldable iPhone Duo, though analysts flagged pricing and margin questions.
Corporate activity included Constellation’s agreement to acquire the company that owns Shell’s Rhode Island State Energy Center for $715 million, a deal that would expand its power-generation portfolio. Separately, Kinetik Holdings is reportedly exploring a potential sale, while Energy Transfer, Sunoco, and others confirmed plans to move their listings from the NYSE to the Texas Stock Exchange. Featured: Top Sub-$1 Silver-Gold Discovery Emerging in North America (Ad) 
| Industrials | |
AeroVironment's (NASDAQ: AVAV) stock price is poised for a full recovery, driven by surging demand and a record-breaking backlog.
Highlights from the company's Q1 include $1.5 billion in funded backlog, up 37% year over year, and $2.8 billion in total backlog, providing clear visibility into the ... Read the Full Story |
| From Our Partners | | Time-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden.
One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone. | | Watch the microscopic footage and learn about the next catalyst |
| Technology | |
When investors consider the physical infrastructure powering artificial intelligence (AI) expansion, semiconductor silicon and power utilities capture most of the attention. Advanced computing clusters and nationwide broadband networks increasingly share another critical physical requirement: high-... Read the Full Story |
| Materials | |
A low share price is attractive to many investors because it allows a meaningful amount of shares to be purchased for a nominal investment. But that doesn't mean a stock offers good value.
To determine that, investors should look at the underlying business. Many of these companies are not yet profi... Read the Full Story |
| From Our Partners | | China controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports to the U.S.
With a January 1, 2027 deadline approaching, the Pentagon selected four companies to build critical mineral processing facilities on U.S. military bases. Only one was chosen for heavy rare earths - a Nasdaq-listed firm with an Ohio metallurgy facility under Pentagon contracts and rights to 80% of output from a major Canadian processing plant. | | See why this rare earth stock deserves a closer look today |
| Technology | |
When governments take direct equity positions in emerging technologies, public markets witness a structural repricing. For years, quantum computing traded like a science experiment, defined by extended hardware timelines and cash burn. That narrative shifted decisively on Sept. 8, 2026, when Washin... Read the Full Story |
| Consumer Discretionary | |
Chewy, Inc.'s (NYSE: CHWY) 2026 price weakness, including its early-September sell-off, looks increasingly disconnected from the company’s operating strength and may give long-term investors an opening. While near-term headwinds cloud the market’s judgment, Chewy is not your typical, cyclical retai... Read the Full Story |
| From Our Partners | | Getting market direction right is only part of an options trade. Strike price, expiration date, and contract cost all shape the outcome.
Trade the Turbulence: Options Strategies for 2026's Politically Charged Volatility breaks down two distinct setups and the decisions behind each, helping traders weigh opportunity against risk. | | Explore the two options setups before your next trade |
| Technology | |
The AI buildout is creating winners across several key industries, including computing, power machinery, and software. Notably, after strong recent performance, three top names across these spaces just saw large bouts of insider selling, totaling over $450 million.
This pattern of sizable gains fol... Read the Full Story |
| Consumer Discretionary | |
GameStop’s (NYSE: GME) Q2 2026 results offer intriguing details suggesting it may be time to take the stock seriously. Maybe. The critical details lie within the Collectibles segment, which has long been the company’s growth focus. It grew 57% year over year to 45.1% of sales and is expected to con... Read the Full Story |
| Technology | |
Braze’s (NASDAQ: BRZE) September price crash looks like a buying opportunity, because the trigger for selling was questionable, and analyst activity has run counter to the move. The trigger was softer-than-expected Q3 guidance that forecast a penny less in earnings than the consensus, an arguably b... Read the Full Story |
| Industrials | |
While most headlines this year have fixated on artificial intelligence, one of the market's quietest and oldest industries has been posting numbers that would make most tech investors jealous. Railroad stocks, the literal backbone of the American economy since the 1800s, are outperforming the broad... Read the Full Story |
| Consumer Discretionary | |
Victoria's Secret & Co. (NYSE: VSXY) just attracted one of the more confusing earnings reactions of the year. The retailer beat Wall Street's earnings estimate comfortably on Sept. 3. Sales were up, adjusted net income soared, and earnings per share beat analysts’ expectations. Yet shares tumbl... Read the Full Story |
| Friday's Early Bird Stock Of The Day UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage. The Optum Health segment provides care delivery, care management, wellness and consumer engagement, and health financial services patients, consumers, care delivery systems, providers, employers, payers, and public-sector entities. The Optum Insight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The Optum Rx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and community health pharmacy services, infusion, and purchasing and clinical capabilities, as well as develops programs in the areas of step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated was founded in 1974 and is based in Minnetonka, Minnesota. | Should I Buy UnitedHealth Group Stock? UNH Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of UnitedHealth Group was last updated on Sunday, October 25, 2026 at 6:31 PM.
UnitedHealth Group Bull Case -
UnitedHealth Group recently delivered a strong third-quarter performance, reporting adjusted earnings per share of $4.69, which significantly exceeded the consensus estimate of $4.14, demonstrating robust cost controls and operational execution that supports investor confidence.
-
Management raised its full-year 2026 adjusted earnings per share outlook to at least $20.50, a significant increase from previous estimates, signaling strong forward-looking profitability and reinforcing the company's ability to generate consistent cash flow for shareholders.
-
The Optum Health segment showed material improvement with profits increasing to $735 million, indicating effective operating leverage and a strengthening of the company's diversified healthcare services business beyond just insurance premiums.
-
Analyst sentiment remains favorable with a consensus rating of Moderate Buy and an average price target of $463.80, which implies potential upside from the current stock price of $417.97, reflecting institutional belief in the company's long-term value proposition.
-
The company maintains a stable dividend yield of 2.18% with a payout ratio of 53.00%, providing a reliable income stream for investors while retaining sufficient capital for growth initiatives and operational needs.
UnitedHealth Group Bear Case -
Planned increases in 2027 Medicare costs for seniors could create political and utilization concerns, potentially pressuring margins and affordability, which may offset some of the recent earnings momentum and create regulatory headwinds.
-
Despite the recent beat, revenue growth has been sluggish, with third-quarter revenue down 0.4% compared to the same quarter last year, suggesting that top-line expansion is not keeping pace with cost management efforts.
-
CEO Patrick Conway has engaged in recent insider selling, including a sale of 1,169 shares in August 2026, which some investors may interpret as a signal of reduced personal conviction in the stock's near-term upside.
-
The stock has experienced volatility, recently falling to $417.97 from a previous close of $424.98, and trading below its 52-week high of $461.62, indicating that the market is still pricing in uncertainty regarding the company's growth path and regulatory environment.
-
Short interest remains present with approximately 15.95 million shares shorted as of the latest record date, suggesting that a portion of the market is betting against the stock's performance, which can contribute to price pressure during periods of negative news.
| | View Today's Stock Pick |
|
| |
|
|
